Our research shows the transformative effect that alemtuzumab can have for people with MS.
Patients who continue to show disease activity while on their initial therapy are especially difficult to treat.
Now, we have shown that alemtuzumab works where first-line drugs have already failed.
It not only reduces the chances of disability associated with MS but may even result in long-term clinical improvements.
More top news
Leaseholds on new-build houses could be banned outright under proposals to stamp out abuses of the system.
Angry protesters have demonstrated outside a police station following the death of a black man who died following a chase.
A heartbroken young mum has issued a poignant plea for a missing teddy bear which plays out the voice of her dead son.